Truist Securities Maintains Buy on Biogen, Lowers Price Target to $340
Portfolio Pulse from richadhand@benzinga.com
Truist Securities analyst Robyn Karnauskas maintains a 'Buy' rating on Biogen (NASDAQ:BIIB) but lowers the price target from $350 to $340.

August 08, 2023 | 4:08 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Biogen's price target has been lowered from $350 to $340 by Truist Securities, though the 'Buy' rating is maintained.
The lowering of the price target by Truist Securities could potentially create a negative sentiment among investors, which might put downward pressure on the stock price. However, the maintained 'Buy' rating indicates that the analyst still sees potential upside, which could counterbalance the negative impact.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100